Drug intelligence / Profile preview

metformin + n-acetylcysteine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of metformin and N-acetylcysteine (NAC) that has been studied for its potential therapeutic effects in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and polycystic ovary syndrome (PCOS). Metformin improves insulin sensitivity and reduces hepatic glucose production, while NAC acts as an antioxidant that replenishes glutathione stores and reduces oxidative stress. The combination appears to have synergistic effects on metabolic parameters, particularly in improving liver histology and biochemical markers.

Other names: n-acetyl cysteine + metforminNAC + metforminN-acetylcysteine + metformin

Targets

SIRT1 (NAD-dependent protein deacetylase sirtuin-1)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on metformin + n-acetylcysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + n-acetylcysteine.

Explore the full profile